The EP PerMed Cell and Gene Therapy Research Call 2027, known as CGT4PM2027, supports international projects developing and validating personalised cell and gene therapies. The call opened on November 4, 2026, with approximately €38 million available across the competition.
Cancer research is eligible alongside other disease areas. Supported approaches include somatic cell therapies, gene therapies, genetically modified cells and qualifying nucleic acid-based treatments. Projects must demonstrate preliminary evidence and a credible pathway toward clinical application.
Eligibility and Project Criteria
- Consortia must include at least three independent, funding-eligible partners from three participating EU Member States or Associated Countries.
- The coordinator must qualify for support from a participating national or regional funder.
- At least one early-career researcher must participate as a principal investigator.
- Academic institutions, research institutes, healthcare organisations, companies and nonprofit organisations may participate, subject to funder rules.
- Projects must develop or validate an innovative personalised cell or gene therapy.
- Relevant preclinical models and solid preliminary data are required.
- Proposals must include a dedicated work package addressing preclinical development and early chemistry, manufacturing and controls.
- Phase I–IV clinical trials, standalone therapeutic-antibody approaches and tumour vaccination approaches are excluded.
Funding Details
- Total call budget: Approximately €38 million.
- Individual funding: Subject to participating national and regional funders’ limits and eligibility rules.
- Funding structure: Joint transnational research funding, co-funded by the European Union.
- Applicants must review the conditions applying to each consortium partner.
Deadline
- Pre-proposals: January 20, 2027, at 2 p.m. CET.
- Invited full proposals: May 25, 2027, at 2 p.m. CEST.
- Expected funding decisions: October–November 2027.
- Expected project start: Late 2027 or early 2028, depending on funder requirements.